Publications

BibTex format

@article{Voysey:2021:10.1016/S0140-6736(20)32661-1,
author = {Voysey, M and Clemens, SAC and Madhi, SA and Weckx, LY and Folegatti, PM and Aley, PK and Angus, B and Baillie, VL and Barnabas, SL and Bhorat, QE and Bibi, S and Briner, C and Cicconi, P and Collins, AM and Colin-Jones, R and Cutland, CL and Darton, TC and Dheda, K and Duncan, CJA and Emary, KRW and Ewer, KJ and Fairlie, L and Faust, SN and Feng, S and Ferreira, DM and Finn, A and Goodman, AL and Green, CM and Green, CA and Heath, PT and Hill, C and Hill, H and Hirsch, I and Hodgson, SHC and Izu, A and Jackson, S and Jenkin, D and Joe, CCD and Kerridge, S and Koen, A and Kwatra, G and Lazarus, R and Lawrie, AM and Lelliott, A and Libri, V and Lillie, PJ and Mallory, R and Mendes, AVA and Milan, EP and Minassian, AM and McGregor, A and Morrison, H and Mujadidi, YF and Nana, A and O'Reilly, PJ and Padayachee, SD and Pittella, A and Plested, E and Pollock, KM and Ramasamy, MN and Rhead, S and Schwarzbold, AV and Singh, N and Smith, A and Song, R and Snape, MD and Sprinz, E and Sutherland},
doi = {10.1016/S0140-6736(20)32661-1},
journal = {The Lancet},
pages = {99--111},
title = {Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK},
url = {http://dx.doi.org/10.1016/S0140-6736(20)32661-1},
volume = {397},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5×1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1-relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23848 participants were enrolled and 11636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pin
AU  - Voysey,M
AU  - Clemens,SAC
AU  - Madhi,SA
AU  - Weckx,LY
AU  - Folegatti,PM
AU  - Aley,PK
AU  - Angus,B
AU  - Baillie,VL
AU  - Barnabas,SL
AU  - Bhorat,QE
AU  - Bibi,S
AU  - Briner,C
AU  - Cicconi,P
AU  - Collins,AM
AU  - Colin-Jones,R
AU  - Cutland,CL
AU  - Darton,TC
AU  - Dheda,K
AU  - Duncan,CJA
AU  - Emary,KRW
AU  - Ewer,KJ
AU  - Fairlie,L
AU  - Faust,SN
AU  - Feng,S
AU  - Ferreira,DM
AU  - Finn,A
AU  - Goodman,AL
AU  - Green,CM
AU  - Green,CA
AU  - Heath,PT
AU  - Hill,C
AU  - Hill,H
AU  - Hirsch,I
AU  - Hodgson,SHC
AU  - Izu,A
AU  - Jackson,S
AU  - Jenkin,D
AU  - Joe,CCD
AU  - Kerridge,S
AU  - Koen,A
AU  - Kwatra,G
AU  - Lazarus,R
AU  - Lawrie,AM
AU  - Lelliott,A
AU  - Libri,V
AU  - Lillie,PJ
AU  - Mallory,R
AU  - Mendes,AVA
AU  - Milan,EP
AU  - Minassian,AM
AU  - McGregor,A
AU  - Morrison,H
AU  - Mujadidi,YF
AU  - Nana,A
AU  - O'Reilly,PJ
AU  - Padayachee,SD
AU  - Pittella,A
AU  - Plested,E
AU  - Pollock,KM
AU  - Ramasamy,MN
AU  - Rhead,S
AU  - Schwarzbold,AV
AU  - Singh,N
AU  - Smith,A
AU  - Song,R
AU  - Snape,MD
AU  - Sprinz,E
AU  - Sutherland,RK
AU  - Tarrant,R
AU  - Thomson,EC
AU  - Török,ME
AU  - Toshner,M
AU  - Turner,DPJ
AU  - Vekemans,J
AU  - Villafana,TL
AU  - Watson,MEE
AU  - Williams,CJ
AU  - Douglas,AD
AU  - Hill,AVS
AU  - Lambe,T
AU  - Gilbert,SC
AU  - Pollard,AJ
AU  - Oxford,COVID Vaccine Trial Group
DO  - 10.1016/S0140-6736(20)32661-1
EP  - 111
PY  - 2021///
SN  - 0140-6736
SP  - 99
TI  - Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
T2  - The Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(20)32661-1
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33306989
UR  - https://www.sciencedirect.com/science/article/pii/S0140673620326611?via%3Dihub
UR  - http://hdl.handle.net/10044/1/85067
VL  - 397
ER  -

Download

Dr David R Owen MD PhD

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)